WEBSITE BSE:0 NSE: Inc. Year: 2012 Industry: Pharmaceuticals & Drugs My Bucket: Add Stock
Last updated: 15:41
No Notes Added Yet
Accent Microcell Ltd. is an India based manufacturer of microcrystalline cellulose (MCC), a refined wood pulp used as a texturizer, an anti-caking agent, a fat substitute, an emulsifier, an extender, and a bulking agent in food production and vitamin supplements. The company was founded in 2012 by Mr. Pratik Patel, who envisioned to create a world-class facility for producing high-quality MCC in India. Since then, They has expanded company's product portfolio to include magnesium stearate, cross carmellose sodium, and cellulose powder. The comp...Read More
Accent Microcell Ltd. is an India based manufacturer of microcrystalline cellulose (MCC), a refined wood pulp used as a texturizer, an anti-caking agent, a fat substitute, an emulsifier, an extender, and a bulking agent in food production and vitamin supplements. The company was founded in 2012 by Mr. Pratik Patel, who envisioned to create a world-class facility for producing high-quality MCC in India. Since then, They has expanded company's product portfolio to include magnesium stearate, cross carmellose sodium, and cellulose powder. The company has also achieved several milestones, such as installing a glass line reactor, using alpha cellulose dissolving rayon grade wood pulp, ranking number one in MCC production in India, having an installed capacity of around 12000 MT annually, and obtaining various quality certificates and approvals. ...Read Less
Our experts help you choose the right stocks based on performance, risk, and growth potential.
Market Cap ₹989 Cr.
Stock P/E 29.9
P/B 5.7
Current Price ₹470
Book Value ₹ 82.4
Face Value 10
52W High ₹474.2
Dividend Yield 0%
52W Low ₹ 191.1
Price goes above X
Price falls below X
PE goes above X
PE falls below X
₹ | |
| #(Fig in Cr.) |
|---|
| Net Sales |
| Other Income |
| Total Income |
| Total Expenditure |
| Operating Profit |
| Interest |
| Depreciation |
| Exceptional Income / Expenses |
| Profit Before Tax |
| Provision for Tax |
| Profit After Tax |
| Adjustments |
| Profit After Adjustments |
| Adjusted Earnings Per Share |
| #(Fig in Cr.) | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|
| Net Sales | 133 | 166 | 197 | 245 | 265 | |
| Other Income | 2 | 2 | 2 | 4 | 6 | |
| Total Income | 135 | 168 | 200 | 249 | 271 | |
| Total Expenditure | 122 | 153 | 178 | 206 | 223 | |
| Operating Profit | 13 | 15 | 21 | 43 | 48 | |
| Interest | 3 | 3 | 3 | 1 | 0 | |
| Depreciation | 4 | 4 | 4 | 4 | 4 | |
| Exceptional Income / Expenses | 0 | 0 | 0 | -1 | 0 | |
| Profit Before Tax | 6 | 8 | 15 | 37 | 44 | |
| Provision for Tax | 1 | 2 | 3 | 6 | 11 | |
| Profit After Tax | 5 | 6 | 12 | 30 | 33 | |
| Adjustments | 0 | 0 | 0 | 0 | 0 | |
| Profit After Adjustments | 5 | 6 | 12 | 30 | 33 | |
| Adjusted Earnings Per Share | 3.7 | 1.5 | 9.5 | 14.3 | 15.7 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | 8% | 17% | 0% | 0% |
| Operating Profit CAGR | 12% | 47% | 0% | 0% |
| PAT CAGR | 10% | 77% | 0% | 0% |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Share Price CAGR | 137% | NA% | NA% | NA% |
| ROE Average | 18% | 25% | 23% | 23% |
| ROCE Average | 24% | 27% | 23% | 23% |
| #(Fig in Cr.) | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|
| Shareholder's Funds | 27 | 32 | 50 | 164 | 195 |
| Minority's Interest | 0 | 0 | 0 | 0 | 0 |
| Borrowings | 18 | 7 | 5 | 1 | 1 |
| Other Non-Current Liabilities | 1 | 2 | 1 | 2 | 2 |
| Total Current Liabilities | 35 | 54 | 56 | 46 | 52 |
| Total Liabilities | 81 | 95 | 113 | 213 | 250 |
| Fixed Assets | 30 | 30 | 31 | 29 | 48 |
| Other Non-Current Assets | 1 | 1 | 2 | 12 | 26 |
| Total Current Assets | 50 | 64 | 80 | 172 | 176 |
| Total Assets | 81 | 95 | 113 | 213 | 250 |
| #(Fig in Cr.) | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|
| Opening Cash & Cash Equivalents | 4 | 0 | 1 | 0 | 2 |
| Cash Flow from Operating Activities | 5 | 15 | 8 | 11 | 25 |
| Cash Flow from Investing Activities | -6 | -4 | -4 | -82 | -9 |
| Cash Flow from Financing Activities | -2 | -10 | -4 | 72 | -14 |
| Net Cash Inflow / Outflow | -3 | 1 | -1 | 1 | 2 |
| Closing Cash & Cash Equivalent | 0 | 1 | 0 | 2 | 4 |
| # | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|
| Earnings Per Share (Rs) | 3.72 | 1.52 | 9.45 | 14.34 | 15.71 |
| CEPS(Rs) | 6.48 | 2.59 | 12.62 | 16.44 | 17.71 |
| DPS(Rs) | 1 | 0.8 | 0.8 | 1 | 1 |
| Book NAV/Share(Rs) | 20.64 | 8.29 | 38.92 | 77.86 | 92.55 |
| Core EBITDA Margin(%) | 8.06 | 7.83 | 9.61 | 16.08 | 15.84 |
| EBIT Margin(%) | 7.08 | 6.43 | 8.79 | 15.35 | 16.67 |
| Pre Tax Margin(%) | 4.53 | 4.58 | 7.5 | 14.88 | 16.54 |
| PAT Margin (%) | 3.62 | 3.56 | 6.2 | 12.29 | 12.5 |
| Cash Profit Margin (%) | 6.3 | 6.06 | 8.28 | 14.09 | 14.09 |
| ROA(%) | 5.95 | 6.72 | 11.77 | 18.47 | 14.27 |
| ROE(%) | 18.04 | 20.07 | 29.67 | 28.17 | 18.44 |
| ROCE(%) | 16.38 | 18.78 | 26.79 | 30.16 | 23.66 |
| Receivable days | 34.72 | 32.66 | 43.85 | 62.56 | 81.86 |
| Inventory Days | 86.87 | 78.34 | 75.42 | 55.7 | 45.95 |
| Payable days | 74.35 | 78.01 | 98.79 | 67.39 | 42.62 |
| PER(x) | 0 | 0 | 0 | 16.21 | 11.49 |
| Price/Book(x) | 0 | 0 | 0 | 2.99 | 1.95 |
| Dividend Yield(%) | 0 | 0 | 0 | 0.41 | 0.52 |
| EV/Net Sales(x) | 0.25 | 0.21 | 0.17 | 1.86 | 1.33 |
| EV/Core EBITDA(x) | 2.59 | 2.31 | 1.57 | 10.61 | 7.29 |
| Net Sales Growth(%) | 0 | 25 | 19.05 | 24.45 | 7.77 |
| EBIT Growth(%) | 0 | 13.58 | 62.67 | 117.36 | 17.07 |
| PAT Growth(%) | 0 | 22.7 | 107.57 | 146.63 | 9.6 |
| EPS Growth(%) | 0 | -59.1 | 520.77 | 51.7 | 9.6 |
| Debt/Equity(x) | 1.15 | 0.75 | 0.45 | 0.08 | 0.01 |
| Current Ratio(x) | 1.43 | 1.19 | 1.43 | 3.7 | 3.38 |
| Quick Ratio(x) | 0.52 | 0.45 | 0.68 | 2.99 | 2.74 |
| Interest Cover(x) | 2.78 | 3.48 | 6.84 | 32.88 | 127.65 |
| Total Debt/Mcap(x) | 0 | 0 | 0 | 0.02 | 0 |
| # | Mar 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| Promoter | 55.09 | 55.09 | 55.09 | 55.09 | 55.44 | 55.44 | 55.47 |
| FII | 0.03 | 0.02 | 0.01 | 0.01 | 0 | 0.29 | 0.58 |
| DII | 1.63 | 1.66 | 2.19 | 2.88 | 3.29 | 3.57 | 3.59 |
| Public | 43.25 | 43.23 | 42.7 | 42.01 | 41.27 | 40.7 | 40.36 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| # | Mar 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| Promoter | 1.16 | 1.16 | 1.16 | 1.16 | 1.33 | 1.33 | 1.33 |
| FII | 0 | 0 | 0 | 0 | 0 | 0.01 | 0.01 |
| DII | 0.03 | 0.03 | 0.05 | 0.06 | 0.08 | 0.09 | 0.09 |
| Public | 0.91 | 0.91 | 0.9 | 0.88 | 0.99 | 0.98 | 0.97 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2.1 | 2.1 | 2.1 | 2.1 | 2.4 | 2.4 | 2.4 |
* The pros and cons are machine generated.
You May Also Know About
Looking to buy unlisted shares or need guidance on the investment process? Our expert Private Equity Advisors are here to assist you with accurate information, real-time pricing, and seamless execution.
Want to sell unlisted shares, liquidate your ESOPs, or understand the step-by-step process of liquidation? Connect with our Buying Team for smooth coordination, quick evaluations, and end-to-end support.
Planning to build or grow your portfolio? For Mutual Fund investments, PMS solutions, tailored portfolio creation, and overall wealth management, our dedicated Wealth Team is ready to guide you.
ChatGPT
Claude
Perplexity
